MRI for MMN and CIDP - Towards improved diagnostic accuracy and dissection of pathophysiology.
Completed
- Conditions
- immuun-mediated/treatable polyneuropathy1000381610034606
- Registration Number
- NL-OMON48985
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 190
Inclusion Criteria
1. Age 18- 80 years.
2. Patients: confirmed diagnosis of CIDP or MMN, as defined by relevant
diagnostic consensus criteria.
3. Disease controls: established diagnosis of relevant clinical mimic to
diagnosis CIDP and MMN (CMT, lower motor neuron syndromes and axonal
neuropathies).
4. Healthy volunteers: no previous diagnosis, sign/symptoms consistent with
neuropathy
Exclusion Criteria
1. age <18 or >80 years,
2. physically unable to undergo MRI or HRUS of the peripheral nervous system
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameters for objective 1, are:<br /><br>1. (Semi-)quantitative rating of MRI-imaging of brachial plexus.<br /><br>2. Cross-sectional area (CSA) on HRUS imaging (CSA measurements of median<br /><br>nerves and brachial plexus).<br /><br>These parameters will be used to select those with highest diagnostic yield as<br /><br>endpoint.<br /><br><br /><br>The main parameters for objective 2, are:<br /><br>1. MRI-DTI values (radial, axial and mean diffusivity (RD, AD and MD),<br /><br>fractional anisotropy (FA)).<br /><br>The will be used to determine the distribution of parameters and nerve size<br /><br>that may be useful in the future for patients with CIDP and MMN. </p><br>
- Secondary Outcome Measures
Name Time Method <p>NA</p><br>